Add time:09/01/2019 Source:sciencedirect.com
IntroductionThere is an unmet need to better control motor complications in Parkinson's disease (PD). naftazone (cas 15687-37-3), which exhibits glutamate release inhibition properties, has shown antiparkinsonian and antidyskinetic activity in preclinical models of PD and in a clinical proof of concept study.
We also recommend Trading Suppliers and Manufacturers of naftazone (cas 15687-37-3). Pls Click Website Link as below: cas 15687-37-3 suppliers
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View